• Hydroxytyrosol for Redox-Causal Assay Design

  2026-08-14

  Hydroxytyrosol can serve as a mechanistically disciplined redox probe for studying nicotine-associated oxidative stress and renal injury. This article translates receptor, ROS, and fibrosis evidence into assay controls, interpretation rules, and reproducible experimental workflows.

• N-Formimidoyl Thienamycin in Resistant Bacteria

  2026-08-14

  This 1982 comparative study evaluated N-formimidoyl thienamycin across 470 clinical isolates, including ampicillin-resistant Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter, enterococci, and oxacillin-resistant staphylococci. Its main contribution was to combine broad comparative MIC testing with bactericidal and β-lactamase-related analysis, revealing strong activity against nonfermenting gram-negative bacteria but uneven superiority across Enterobacteriaceae.

• Dicloxacillin Activity Against Intracellular S. aureus

  2026-08-13

  The reference study combined macrophage-based infection assays, a murine peritonitis model, and PK/PD analysis to define dicloxacillin activity against intracellular and extracellular Staphylococcus aureus. Its central finding was that free-drug exposure above the MIC was the most informative efficacy index in both compartments, while model timing strongly influenced apparent extracellular killing.

• Cinoxacin: Quinolone Antibiotic Research Guide

  2026-08-13

  Cinoxacin is a quinolone antibiotic with reported activity against several clinically relevant Gram-negative uropathogens. Its documented DNA-replication inhibition, MIC range, solubility profile, and urinary pharmacokinetics make it useful for structured urinary tract infection research and antibiotic resistance studies.

• PLGA Nano-Adjuvant Enhances Mucosal Immunity in Chicks

  2026-08-12

  A 2026 Poultry Science study developed PEI-LSP-RA-PLGA, a PLGA-based nanoadjuvant designed to combine sustained release, intestinal targeting, and immune regulation for an inactivated H9N2 avian influenza vaccine. The formulation enhanced systemic IgG, intestinal IgA, immune-organ responses, and pathway-associated mucosal immunity in chicks, although further work is needed to establish dose dependence, long-term safety, and protection against viral challenge.

• CHIR-99021 (CT99021): GSK-3 Stem Cell Guide

  2026-08-12

  CHIR-99021, also called CT99021, is a selective GSK-3α/β inhibitor used to modulate Wnt/β-catenin signaling in stem-cell and differentiation workflows. Its reported biochemical potency, solvent limitations, and pathway-dependent effects make assay design and exposure control essential.

• HBoV1 Replication, DNMT1, and NS1-Mediated RNA Control

  2026-08-11

  A 2024 PLOS Pathogens study shows that HBoV1 uses host DNA methylation and DNMT1 to support viral DNA synthesis while restraining RNA processing. Its key mechanistic insight is that NS1 promotes DNMT1 degradation through the ubiquitin–proteasome pathway, linking viral replication control with production of protein-encoding transcripts.

• Linezolid: Mechanism to Assay Strategy

  2026-08-11

  Linezolid is an oxazolidinone antimicrobial for rigorous studies of bacterial protein synthesis, MRSA, VRE, and bacterial pneumonia. This article connects its ribosomal mechanism with assay design and uses recent MmpL3 research to clarify how cross-domain evidence should—and should not—guide interpretation.

• Nipah Virus Polymerase Structure and Antiviral Design

  2026-08-10

  The reference study defines the architecture of the Nipah virus L-P polymerase complex using cryo-electron microscopy, X-ray crystallography, and integrative modelling. Its findings clarify how polymerase domains and the P-protein assemble, while identifying a metal-binding feature that may contribute to mRNA capping and future antiviral design.

• Cinoxacin: Mechanism, Spectrum, and UTI Evidence

  2026-08-09

  The reference study positioned Cinoxacin as a clinically useful quinolone antibiotic by integrating its bacterial DNA synthesis mechanism, activity against urinary gram-negative pathogens, pharmacokinetics, tolerability, and therapeutic evidence. Its main practical contribution was linking rapid urinary exposure and Enterobacteriaceae activity to treatment and prophylaxis strategies for bacterial urinary tract infections.

• Streptavidin – Cy5 for Reliable Cell Assays

  2026-08-08

  Learn how Streptavidin – Cy5 (SKU K1080) can strengthen biotin-based fluorescence workflows used alongside cell viability, proliferation, apoptosis, and cytotoxicity assays. This scenario-driven guide connects spectral selection, storage, controls, interpretation, and vendor evaluation to practical laboratory decisions.

• Propidium Iodide for Toxoplasma Cell Death Assays

  2026-08-07

  Learn how Propidium iodide turns membrane damage into a measurable endpoint for Toxoplasma gondii infection, GRA12 perturbation, viability testing, and cell-cycle profiling. The workflow combines practical PI staining with Annexin V, imaging, and genetic controls to distinguish parasite-associated host-cell injury from assay artifacts.

• Screening MMV Pandemic Box: New Leads Against MDR Pathogens

  2026-08-07

  This study systematically screened 247 compounds from the MMV Pandemic Response Box to identify agents effective against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and clinically relevant fungi. The findings highlight promising candidates for further development and inform future antimicrobial and biofilm inhibition research.

• TCF25 Controls Lysosomal Acidification in Glucose Starvation

  2026-08-06

  Ren et al. (2025) reveal TCF25 as a nutrient sensor that orchestrates metabolic adaptation and cell death during glucose deprivation by enhancing lysosomal acidification via V-ATPase. These findings clarify how cells shift from survival-promoting autophagy to lysosome-dependent cell death under metabolic stress, highlighting TCF25 as a potential therapeutic target for metabolic and ischemic diseases.

• HAUS1 as a Prognostic Biomarker and Immune Modulator in HCC

  2026-08-06

  The referenced study reveals that HAUS1 is highly expressed in hepatocellular carcinoma (HCC) and is linked to poor prognosis, tumor progression, and immune microenvironment alterations. These findings highlight HAUS1's potential as a diagnostic, prognostic, and therapeutic target, underscoring new avenues for biomarker-driven cancer research and therapy.

8048 records 2/537 page Previous Next 12345 下5页 Last page